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Abstract
Focal epileptic seizures can in some patients be managed by inhibiting γ-aminobutyric acid (GABA) uptake via the GABA 
transporter 1 (GAT1) using tiagabine (Gabitril®). Synergistic anti-seizure effects achieved by inhibition of both GAT1 and 
the betaine/GABA transporter (BGT1) by tiagabine and EF1502, compared to tiagabine alone, suggest BGT1 as a target in 
epilepsy. Yet, selective BGT1 inhibitors are needed for validation of this hypothesis. In that search, a series of BGT1 inhibitors 
typified by (1R,2S)-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-yl)(methyl)amino)cyclohexanecarboxylic acid (SBV2-114) 
was developed. A thorough pharmacological characterization of SBV2-114 using a cell-based  [3H]GABA uptake assay at 
heterologously expressed BGT1, revealed an elusive biphasic inhibition profile with two  IC50 values (4.7 and 556 μM). The 
biphasic profile was common for this structural class of compounds, including EF1502, and was confirmed in the MDCK 
II cell line endogenously expressing BGT1. The possibility of two binding sites for SBV2-114 at BGT1 was assessed by 
computational docking studies and examined by mutational studies. These investigations confirmed that the conserved resi-
due Q299 in BGT1 is involved in, but not solely responsible for the biphasic inhibition profile of SBV2-114. Animal stud-
ies revealed anti-seizure effects of SBV2-114 in two mouse models, supporting a function of BGT1 in epilepsy. However, 
as SBV2-114 is apparent to be rather non-selective for BGT1, the translational relevance of this observation is unknown. 
Nevertheless, SBV2-114 constitutes a valuable tool compound to study the molecular mechanism of an emerging biphasic 
profile of BGT1-mediated GABA transport and the putative involvement of two binding sites for this class of compounds.
Keywords GABA uptake · GAT1 · Homology modelling · Epilepsy · Q299L
Introduction
γ-Aminobutyric acid (GABA) is the main inhibitory neuro-
transmitter in the central nervous system (CNS) and is criti-
cal for maintaining normal neurotransmission. An imbalance 
between excitatory and inhibitory signalling is reported in 
several neurological disorders including epilepsy, Alzhei-
mer’s disease, and ischemia [1–7]. Accordingly, enhanced 
GABAergic signalling may counterbalance the excessive 
excitatory neurotransmission and alleviate seizures in 
patients [8]. Fast inhibitory neurotransmission by GABA 
is mediated through ligand-gated ionotropic  GABAA recep-
tors [9, 10], which are favoured therapeutic targets. Another 
way to enhance GABAergic signalling is by inhibition of 
the GABA transporters (GATs), thereby increasing extracel-
lular GABA levels causing indirect inhibition [11, 12]. The 
GATs are transmembrane proteins comprised by four distinct 
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transporters named GAT1, GAT2, GAT3 and BGT1 [13], 
according to the IUPHAR nomenclature [14]. GATs belong 
to the solute carrier 6 (SLC6) transporter family along with 
e.g. the serotonin transporter (SERT) for which crystal and 
cryo-electron microscopy structures have been solved [15, 
16]. Due to the abundance of GAT1 in the CNS, most GAT 
research has been directed at this subtype, which led to the 
first antiepileptic drug, tiagabine (Gabitril®) (Fig. 1), tar-
geting a GAT [17]. However, the substantial side effects of 
tiagabine [18, 19], together with studies of BGT1 inhibi-
tors showing anti-seizure effects [20–23], have prompted 
research into this subtype as well. Specifically, the BGT1/
GAT1 mixed inhibitor EF1502 and the BGT1 selective 
inhibitor RPC-425 (Fig. 1) [20] have been found to present 
anti-seizure effects in mouse models, suggesting a role for 
BGT1 in epilepsy [20–23]. Of particular relevance, BGT1 
has been proposed to induce an extrasynaptic protecting 
mechanism following excitotoxic brain injury [24, 25]. 
Additionally, reported increases in BGT1 expression lev-
els after epileptic insults in patients and animal models [8] 
support a potential role for BGT1 during certain pathologi-
cal conditions. The role of BGT1 in seizure management, 
however, is questioned by the unchanged seizure threshold 
in BGT1 knock out (KO) mice [26], although compensatory 
mechanisms from the remaining GATs could have masked 
the effect of deleting BGT1 [27–29]. Thus, to shed light on 
the function of BGT1 in pathologies like epilepsy selective, 
brain-permeant compounds are desirable. To date, only a 
limited number of brain-permeant tool compounds, spe-
cifically targeting BGT1, are available [27]. In the further 
development of BGT1 ligands, the previous partial success 
of using β-amino acid-containing derivatives such as RPC-
425 and EF1502, was extended. This led to the synthesis 
of (1R,2S)-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-
yl)(methyl)amino)cyclohexanecarboxylic acid ((1R,2S)-
5a, SBV2-114), derived from tiagabine (Fig. 1) [20, 30]. 
SBV2-114 was found to be an inhibitor of BGT1 with a 
potency in the mid μM range and with > 13 fold selectiv-
ity for BGT1 over the other GAT subtypes [30]. Looking 
further into the uptake inhibition profile revealed an unu-
sual biphasic inhibition profile of SBV2-114 at BGT1. Also, 
anti-seizure effects of SBV2-114 in two mouse models was 
demonstrated, substantiating the involvement of BGT1 in 
epilepsy. To our knowledge this is the first example of a 
biphasic ligand profile at a GABA transporter and the class 
of compounds including SBV2-114, may ultimately contrib-
ute to our understanding of GAT transport mechanisms and 
further the pharmacological studies of BGT1 as a drug target 
in epilepsy.
Materials and Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM) with Glu-
taMAX-I, Hank’s Balanced Salt Solution (HBSS), fetal 
bovine serum (FBS), and penicillin–streptomycin (P/S) 
were purchased from Life Technologies (Paisley, UK). 
PolyFect Transfection Reagent was purchased from Qiagen 
(West Sussex, UK). HEPES (4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid), Poly-d-lysine (PDL), ATP (adeno-
sine 5′-triphosphate), U-73122,  CaCl2, and  MgCl2 were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
tetrakis(acetoxymethyl ester) (BAPTA/AM) was purchased 
from Millipore (Billerica, MA, USA) while BAPTA, Fluo-4 
loading dye, Pluronic F-127, and probenecid were pur-
chased from ThermoFisher Scientific (Waltham, MA USA). 
1-[3-(9H-Carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-pi-
peridinol (NNC 05–2090) and A 804598 were purchased 
from Tocris Bioscience (Bristol, UK). [2,3-3H(N)]GABA 
(35.0 Ci/mmol) and Micro-Scint-20 were purchased from 
PerkinElmer (Boston, MA, USA).
(R)-4-((4,4-bis(3-methylthiophen-2-yl)butyl)(methyl)
amino)-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol ((R)-
EF1502), (1R,2S)-2-((4,4-bis(3-methylthiophen-2-yl)
but-3-en-yl)(methyl)amino)cyclohexanecarboxylic 
acid ((SBV2-114), (1R,2S)-5a), (1R,2R)-2-((4,4-bis(3-
methylthiophen-2-yl)but-3-en-1-yl)(methyl)amino)
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Fig. 1  Structure of GABA, BPDBA (N-(1-benzyl-4-piperidinyl)-
2,4-dichlorobenzamide),  tiagabine, EF1502 ([N-[4,4-bis(3-
methyl-2-thienyl)-3-butenyl]-3-hydroxy-4-(methylamino)-
4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol]), RPC-425 
(6-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)amino)
cyclohex-1-ene-1-carboxylic acid), and SBV2-114 ((1R,2S)-2-((4,4-
bis(3-methylthiophen-2-yl)but-3-en-yl)(methyl)amino)cyclohexane-
carboxylic acid)
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cyclohexane-1-carboxylic acid ((1R,2R)-4a), (1S,2R)-
2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)
amino)cyclohexane-1-carboxylic acid ((1S,2R)-5a), 
(1S,2R)-2-((3-(10,11-dihydro-5H-dibenzo[a,d][7] annulen-
5-ylidene)propyl)(methyl)amino)cyclohexane-1-carboxylic 
acid ((1S,2R)-5c), and N-(1-benzyl-4-piperidinyl)-2,4-di-
chlorobenzamide (BPDBA) were synthesized in-house 
as previously described [23, 30, 31]. The Madin-Darby 
canine kidney (MDCK) II cell line was kindly provided by 
Dr. Hanne Borger Rasmussen (University of Copenhagen, 
Denmark).
Cell Culturing and Transient GAT Expression
The HEK-293 and Flp-In CHO cell lines stably expressing 
mouse (m) and human (h) GATs, respectively, have been 
described previously and were cultured accordingly [31–33]. 
The tsA201 cell line was used for transient expression while 
the MDCK II cell line express BGT1 endogenously [34]. 
Both cell lines were cultured as described [33, 35]. tsA201 
cells were transfected with DNA constructs (8 μg per 10 cm 
dish if not otherwise mentioned) using 40 μL PolyFect trans-
fection reagent according to the manufacturer’s protocol 
(Qiagen, Venlo, Netherlands). The DNA constructs encod-
ing hBGT1, hGAT1-3 [36], the mutated constructs hBGT1 
Q299 and hGAT3 L314Q described previously [37], and 
hBGT Y453A were synthesized and sequence validated by 
Genscript (NJ, USA).
[3H]GABA Uptake Assays
The  [3H]GABA competition uptake assay was performed as 
previously described [36]. A minor change, however, was 
introduced for uptake in MDCK II cells, in which 100 nM 
 [3H]GABA was used for a 15 min incubation period at 37 °C 
instead of 30 nM  [3H]GABA and 3 min incubation. Studies 
related to the inhibition curves with GABA and BPDBA at 
hBGT1 were obtained both with and without the presence of 
10 μM ATP during the  [3H]GABA uptake assay.
To examine the influence of  Ca2+ on the functional activity, 
tsA201 cells were pre-incubated with 25 μM BAPTA, 25 μM 
BAPTA/AM, 5 μM U-73122 or 1 μM A804598 in assay 
buffer for 30 min prior to the  [3H]GABA uptake to ensure that 
the compounds reached their site of action. All compounds, 
except BAPTA/AM, were also present at the same concentra-
tion during the course of the actual  [3H]GABA uptake assay.
The  [3H]GABA uptake data was normalized to the per-
centage of total uptake in the individual experiments in the 
presence of the lowest compound concentration or no com-
pound present. Data presented is the pooled data of at least 
three independent experiments with three technical repli-
cates. Concentration–response curves (CRCs) were fitted 
with GraphPad Prism (version 8.2.1, Yosemite, GraphPad 
Software, San Diego, CA, USA) by non-linear regression to 
the sigmoidal concentration response model:
where Top is the Top plateau, Bottom is the Bottom plateau, 
X is the logarithm of the concentration of the compound, 
 LogIC50 is the concentration giving a response halfway 
between Top and Bottom,and nH is the Hill slope.
And the biphasic model:
where Bottom and Top are the plateaus at the left and right 
ends of the curve, in the same units as Y.  LogIC50_1 and 
 LogIC50_2 are the concentrations that give half-maximal 
inhibitory effects. nH1 and nH2 are the Hill slopes and Frac 
is the proportion of maximal response due to the more potent 
phase.
The best fit for CRCs obtained with the  [3H]GABA 
uptake assay was identified by the extra-sum-of-squares F 
test (for convenience referred to as F test).
Modeling
A hBGT1 homology model based on the hSERT crys-
tal structure PDB ID 5I73 [15] was used from Jørgensen 
et al. [37]. Protein and ligand preparation were performed 
with PrepWiz [38] and LigPrep [39], respectively, in the 
Schrödinger Suite 2015-2. Flexible side chain docking was 
performed with GOLD 5.2.2 [40] into the orthosteric and 
allosteric site corresponding to the orthosteric and allos-
teric sites in the crystal structure 5I73 (hBGT1 orthosteric 
site residues (flexible side chains in italics); Glu52, Ile53, 
Ile54, Gly55, Ile125, Glu126, Leu129, Asn130, Tyr132, 
Tyr133, Phe293, Ser294, Phe295, Ala296, Gln299, Cys301, 
Gly392, Ser395, Gln396, Val398, Cys399, Ser456, Ser457, 
Leu461; allosteric site residues: Trp60, Leu56, Arg61, 
Tyr132, Tyr133, Ile136, Asp286, Thr289, Gln290, Phe293, 
Ser294, Phe448, Asp452, Tyr453, Ser457, Gly458, Ile459, 
Ser516, Tyr520, Thr521). 100 SBV2-114 poses per site 
were generated and scored according to the internal GOLD 
5.2.2 ChemPLP scoring function [37] as well as rescored 
with GBVI/WSA dG and London dG scoring functions 
Y = Bottom +
(Top − Bottom)
1 + 10(LogIC50−X)∗nH
Section1 = (Top − Bottom)∗
Frac
1 + 10(LogIC50_1−X)∗nH1
,
Section2 = (Top − Bottom) ∗
(1 − Frac)
1 + 10(LogIC50_2−X)∗nH2
,
Y = Bottom + Section1 + Section2
1554 Neurochemical Research (2020) 45:1551–1565
1 3
implemented in Moe [41]. Visual inspection of all poses 
was performed with Moe [41].
Fluo‑4  Ca2+‑Assay
SBV2-114 was tested for its ability to induce  Ca2+ increases 
in tsA201 cells transiently expressing hBGT1 or hGAT1 by 
the Fluo4  Ca2+-assay as previously described with minor 
changes [42]. In brief, 4 μM Fluo-4 loading dye was mixed 
with 0.004% Pluronic F-127 and dissolved in HBSS buffer 
with 20 mM HEPES, 1 mM  CaCl2 and 1 mM  MgCl2 (HBSS-
HEPES) supplemented with 2.5 mM probenecid. 50 μL of 
the loading buffer was added to each 96 well before incu-
bating the cells 60 min at 37 °C. Cells were then washed 
with HBSS-HEPES buffer before changes in intracellular 
 Ca2+ were recorded for 190 s. on a Flexstation 3 Benchtop 
multi-mode microplate reader (Molecular Devices, Sunny-
vale, CA, USA) at 37 °C with an λex of 485 nm and λem 
of 525 nm. Emission was recorded for 20 s. before adding 
the compounds (at 4 × concentrations) to the HBSS-HEPES 
buffer to determine the baseline. The changes in fluorescence 
in the Fluo-4  Ca2+-assay were normalized to the percentage 
of the maximum response elicited by 100 μM ATP in the 
individual experiments. Data presented is the pooled data 
of at least three independent experiments with three techni-
cal replicates. Changes in fluorescence units (ΔFU) were 
determined as the maximum fluorescent signal within the 
190 s minus the average of the baseline.
Animals
Male audiogenic-susceptible (AGS) Frings mice were 
obtained from an in-house breeding facility at the Univer-
sity of Utah (Salt Lake City, UT, USA). Male CF-1 mice 
for the maximal electroshock (MES) test and the subcutane-
ous pentylenetetrazol (s.c.PTZ) seizure threshold test were 
purchased from Charles River (Kingston, WA, USA). All 
mice were housed in a temperature, humidity, and light (on 
at 6:00 AM) controlled facility at the University of Utah 
with access to ad libitum food and water except during test-
ing. All procedures were carried out at the University of 
Utah in concordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and 
under approval from the University of Utah’s Institutional 
Animal Care and Use Committee. The mice were euthanized 
in accordance with Public Health Service policies on the 
humane care of laboratory animals.
Audiogenic Seizures
The ability of SBV2-114 to prevent sound-induced sei-
zures was studied in AGS Frings mice. The seizures were 
induced as previously described [20]. In brief, Frings mice 
were placed in a Plexiglas cylinder (diameter 15 cm, height 
18 cm) connected to an audio transducer and exposed to 
a sound stimulus of 110 decibel (11 kHz) for a duration 
of 20 s. SBV2-114 (50 and 120 mg/kg, n = 4) was injected 
intraperitoneal (i.p.) at various time points to determine the 
time-to peak (TPE). The mice were considered protected if 
they failed to display full hind limb tonic extension seizures. 
All Frings mice were pre-screened the day prior to testing 
and only those mice that displayed a tonic extension sei-
zure in response to the sound stimulus were included in the 
SBV2-114 studies.
Maximal Electroshock (MES) Test
The ability of SBV2-114 to prevent electroshock-induced 
seizures was assessed using the MES test. This is a model 
of generalised tonic–clonic seizures, and was conducted as 
described previously [21]. In brief, a drop of anaesthetic/
electrolyte solution (0.5% tetracaine hydrochloride in 0.9% 
saline) was applied to the cornea of each animal prior to 
placement of the silver-coated corneal electrodes. An alter-
nating current of 50 mA (60 Hz) was delivered for 0.2 s to 
the cornea of the mouse using a Woodbury–Davenport stimu-
lator. The supramaximal current applied to the cornea was 
sufficient to induce maximal tonic extension seizures in all 
non-treated mice. Separate groups of mice were treated with 
increasing doses of SBV2-114 (50–200 mg/kg, i.p., n = 3–7) 
and were exposed to the MES stimulus at the predetermined 
SBV2-114 TPE; i.e., 15 min. Those mice not displaying full 
hind limb tonic extension seizures were considered protected.
Subcutaneous Pentylenetetrazol Seizure Test
SBV2-114 was tested for its ability to prevent a minimal 
clonic seizure in the s.c.PTZ seizure test, which is a test 
of generalized myoclonic seizures. The s.c.PTZ seizure test 
was carried out as previously described [21], and SBV2-114 
was injected i.p. at a dose of 150 mg/kg (n = 8). At the TPE, 
mice were challenged with a s.c. dose of PTZ (85 mg/kg) 
and observed for 30 min for the presence or absence of a 
minimal clonic seizure characterized by minimal forelimb 
clonus and/or vibrissae twitching. Mice not displaying this 
phenotypic behaviour were considered protected.
Behavioural Impairment
Minimal motor impairment of mice receiving SBV2-114 
was evaluated using the rotarod procedure [43]. Impairment 
was noted if the mice failed to maintain their equilibrium 
for 1 min in three consecutive trials on a one-inch rotating 
rod (6 rpm). The rotarod test was performed just prior to the 
three seizure tests.
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Quantification of Anti‑seizure Efficacy 
and Behavioural Impairment
Probit analysis [21] was used to analyse the efficacy and 
tolerability results obtained from the dose–response stud-
ies and to calculate the median effective  (ED50) dose, the 
median toxic dose  (TD50), and the 95% confidence interval.
Screening for Selectivity
The selectivity of SBV2-114 for BGT1 for 42 different neu-
roreceptors and transporters was tested by examining the 
affinity of SBV2-114 in radioligand binding assays at the 
National Institute of Mental Health’s Psychoactive Drug 
Screening Program (NIMH PDSP, Contract # HHSN-271-
2008-00025-C). SBV2-114 was tested at a concentration of 
10 μM followed by full curves if inhibition exceeded 50% 
at 10 μM.
Statistical Analysis
All statistical and pharmacological analyses were performed 
using GraphPad Prism (version 8.2.1, Yosemite, GraphPad 
Software, San Diego, CA, USA), and appropriate statistical 
tests are specified accordingly.  Level of significance was 
set at P < 0.05.
Results
Identification of a Biphasic Inhibition Profile 
of SBV2‑114 at BGT1
Previous studies in our group have revealed that SBV2-
114 has a potency in the mid μM range for mBGT1 and 
displays about 26, 43 and 13 times reduced inhibitory 
potency at mGAT1, mGAT2 and mGAT3, respectively 
[30]. In this study, a thorough pharmacological charac-
terization of SBV2-114 using the competitive  [3H]GABA 
uptake assay was performed. This entailed 12 concentra-
tions to generate a detailed CRC. This study revealed that 
SBV2-114 inhibited mBGT1 (stably expressed in HEK-
293 cells) and hBGT1 (transiently expressed in tsA201 
cells) in an unusual biphasic manner (confirmed by F tests) 
with  IC50 values in the low (m/hBGT1: 3.8/4.7 μM) and 
high μM range (m/hBGT1: 402.7/555.9 μM) correspond-
ing to the high and low affinity components, respectively 
(Fig. 2a and Table 1). The % inhibition (Frac value) at the 
low  IC50 was 45% at mBGT1 and 42% at hBGT1. This 
biphasic behaviour was not seen in previously performed 
8-point mBGT1 inhibition CRCs [30]. In comparison, the 
endogenous ligand GABA, the BGT1 inhibitor BPDBA 
(Fig. 2a, Supplemental Fig. 2b), and the conventional 
GAT1 inhibitor tiagabine all inhibit  [3H]GABA uptake in 
a clearly monophasic manner [36]. Furthermore, the  IC50 
values of SBV2-114 were in the same range regardless of 
the amount of plasmid DNA used for the transient expres-
sion of hBGT1 (Supplemental Table 1) indicating that the 
biphasic inhibition profile at BGT1 was not influenced by 
the expression level of BGT1. 
To investigate if the biphasic inhibition profile of SBV2-
114 was a consequence of recombinant overexpression in 
Fig. 2  Inhibitory activity of SBV2-114 at mouse, human and canine 
BGT1. (a) SBV2-114 and GABA were tested for their ability to 
inhibit uptake of 30 nM  [3H]GABA for 3 min at mBGT1 and hBGT1 
in HEK-293 and tsa201 cells, respectively, and (b) 100  nM  [3H]
GABA for 15  min at canine BGT1 in MDCK II cells. The experi-
ments were performed in triplicate in four-five independent experi-
ments and depicted as normalized means ± S.E.M. The data fitting is 
based on the preferred model according to the extra-sum-of-squares F 
test (see Table 1 for details). Typical counts ranged from 100 to 8000 
CPM at hBGT1 and mBGT1 and 500 to 2000 CPM at canine BGT1
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the heterologous expression system, SBV2-114 was tested at 
MDCK II cells endogenously expressing canine BGT1 [34]. 
In this study with MDCK II cells, SBV2-114 retained its 
biphasic inhibition profile (P = 0.0067, F test) at BGT1 with 
 IC50 values of 0.1 μM and 250.6 μM (Fig. 2b and Table 1) 
supporting the finding that the biphasic inhibition profile of 
SBV2-114 at BGT1 is not a phenomenon only seen in over-
expressed cells and is independent of the species.
To ascertain whether the biphasic CRC of SBV2-114 at 
BGT1 was caused by kinetic factors, e.g. by a slower on-
kinetics, tsA201 cells expressing hBGT1 were pre-incubated 
for 10 min with SBV2-114 prior to the  [3H]GABA uptake 
assay. This had no impact on the curve fitting and the bipha-
sic fit was still preferred (P < 0.0001, F test, data not shown) 
although pre-incubation reduced the % inhibition at the low 
 IC50 as the Frac value decreased from 0.45 to 0.34.
To test whether the biphasic inhibition profile was con-
fined to BGT1, the detailed pharmacological characterization 
of SBV2-114 was extended to mGAT1-3 stably expressed 
in HEK-293 cells [32] and hGATs stably expressed in Flp-
In CHO cells [36]. It is clear that SBV2-114 did not inhibit 
the m/hGAT1-3 in a typical monophasic manner (Supple-
mental Tables 2 and 3). Specifically, the fitting of the inhi-
bition profile of SBV2-114 was predominantly ambiguous, 
meaning neither fitted to a monophasic or biphasic profile, 
at mGAT1-3-HEK-293 with  IC50 values > 1000 μM (Sup-
plemental Table 2). SBV2-114 also produced ambiguous fit-
ting results at the hGATs (Supplemental Table 3). In detail, 
SBV2-114 inhibited the  [3H]GABA uptake at hBGT1-CHO 
in a biphasic manner in two out of four experiments, and 
with a reduced % inhibition at the low  IC50 (Frac = 0.10). 
Additionally, SBV2-114 displayed a biphasic inhibition pro-
file at hGAT3, but also with a reduced Frac value compared 
to hBGT1-tsA, and in one out of four experiments at GAT2 
(Supplemental Table 3). These data collectively show that 
SBV2-114 generally inhibits the  [3H]GABA uptake by m/
hGATs in an atypical manner.
Several Structurally Related SBV2‑114 Analogues 
Also Inhibit BGT1 in a Biphasic Manner
To investigate whether the biphasic inhibition profile at 
BGT1 is unique to SBV2-114, we also characterized the 
inhibition profile of a number of different compound classes 
in the  [3H]GABA uptake assay (Table 2). We tested three 
compounds that all contain a β-amino acid moiety like 
SBV2-114, but with varying stereochemistry and differ-
ent di-aromatic lipophilic side-chains including (1R,2R)-
4a, (1S,2R)-5a, and (1S,2R)-5c [30]. (R)-EF1502 was also 
included in the detailed pharmacological characterization, 
with no prior notion of a biphasic inhibition profile, as it is 
structurally highly similar to SBV2-114. Finally, two BGT1 
inhibitors belonging to other compound classes namely 
BPDBA [31] and NNC 05-2090 [44] were included (Fig. 1). 
Convincingly, all compounds containing a β-amino acid 
moiety with di-aromatic lipophilic side-chains including 
(R)-EF1502 showed a biphasic CRC at hBGT1 transiently 
expressed in tsA201 cells. The most potent component of 
the biphasic response ranged from 2.5–11.2 μM inhibiting 
a fraction of 0.19–0.42, where the largest inhibition was 
observed with SBV2-114. The high  IC50 values ranged from 
190.5 to 818.5 μM (Table 2). (R)-EF1502 and SBV2-114 
were the compounds with the highest F value, respectively, 
and hence statistically, the ones with the most distinct bipha-
sic CRCs. BGT1 inhibitors, not comprising a β-amino acid 
moiety attached to di-aromatic lipophilic side-chains, such 
as BPDBA and NNC 05–2090, did not inhibit hBGT1 in a 
biphasic manner (Table 2, Supplemental Fig. 2b).
Investigations into the Possible Mechanisms 
of Action
Having verified the biphasic response of SBV2-114 and 
structurally related compounds at BGT1 in the  [3H]GABA 
uptake assay, we wanted to address the molecular details. 
To this end, the possibility of SBV2-114 binding to two 
Table 1  Inhibitory activity of SBV2-114 at mouse, human and canine BGT1. SBV2-114 was tested for its ability to inhibit uptake of  [3H]GABA 
(see Fig. 1 for details)
All experiments were performed in triplicate in four-five independent experiments. The data fitting is based on the preferred model according to 
the extra-sum-of-squares F test, and the associated P, F, DFn, DFd, Frac values, and  nH1,  nH2 are indicated
a mouse BGT1 stably expressed in HEK-293 cells, human BGT1 transiently expressed in tsA201 cells, and canine BGT1 endogenously expressed 
in MDCK II cells
[3H]GABA uptake at BGT1 Extra-sum-of-squares F test
Speciesa IC50  (pIC50 ± S.E.M.) (μM) P value F value DFn, DFd Frac nH1,  nH2
Mouse 3.8 (5.42 ± 0.08) 408.3 (3.39 ± 0.03) < 0.0001 10.6 3, 53 0.45 − 0.62, − 2.61
Human 4.7 (5.28 ± 0.10) 555.9 (3.26 ± 0.03) < 0.0001 11.2 3, 53 0.42 − 0.86, − 2.13
Canine 0.1 (6.98 ± 0.79) 250.6 (3.60 ± 0.10) 0.0067 5.7 2, 41 0.38 − 0.62, − 1.97
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non-equal binding sites in BGT1 was investigated. Further, 
the influence of  Ca2+ on the inhibition profile was exam-
ined due to the link between intracellular  Ca2+ changes and 
altered  [3H]GABA uptake [45].
Could SBV2‑114 Bind to Two Non‑equal Binding 
Sites?
The fact that SBV2-114 clearly inhibits BGT1 in a bipha-
sic manner with two distinct  IC50 values could suggest that 
SBV2-114 possibly binds to two different sites in BGT1. 
This is in line with recent crystallographic evidence that the 
antidepressant escitalopram not only binds to the orthosteric 
pocket of the human SERT, but also to an allosteric pocket 
in the extracellular vestibule above the orthosteric site [15]. 
Since hSERT is highly related to hBGT1 (44% sequence 
identity), both belong to the SLC6A family as well as share 
the same fold, it is very likely that a similar allosteric bind-
ing site exist in BGT1 and the other GATs [13, 15, 37, 46, 
47].
To address the possibility of two binding sites for SBV2-
114 at BGT1, SBV2-114 was docked into the orthosteric 
and allosteric site of a hBGT1 homology model based on 
the hSERT crystal structure PDB ID 5I73 co-crystallized 
with escitalopram in the orthosteric and allosteric site [15, 
37]. After visually investigating the top scored poses of 
Table 2  Chemical structures of SBV2-114, selected SBV2-114 analogues and other tested BGT1 inhibitors and their inhibitory activity at 
hBGT1 transiently expressed in tsA201 cells
[3H]GABA uptake at BGT1 Extra-sum-of-squares F test
Compound Structure
IC50 (μM)
(pIC50 ± S.E.M.)
P value F value DFn,
DFd
Frac nH1,
nH2
(1R,2S)-5a 
SBV2-114
4.7
(5.28 ± 0.10)
555.9
(3.26 ± 0.03)
< 0.001 11.19 3, 53 0.42 – 0.86,
– 2.13
(1R,2R)-4a 3.4
(5.47 ± 0.01)
566.2
(3.25 ± 0.03)
0.001 8.56 2, 30 0.19 – 1.68,
– 1.90
(1S,2R)-5a 4.7
(5.33 ± 0.10)
369.8
(3.43 ± 0.04)
0.001 9.49 2, 30 0.28 – 0.98,
– 2.10
(1R,2S)-5c 11.2
(4.95 ± 0.10)
818.5
(3.09 ± 0.04)
0.022 5.55 2, 30 0.26 – 1.14,
– 2.13
(R)-EF1502 2.5
(5.61 ± 0.41)
190.5
(3.72 ± 0.12)
< 0.001 24.1 2, 28 0.30 –0.79,
–2.35
BPDBA 14.8
(4.82 ± 0.057)
n.s.
NNC 05-2090 116.9
(3.93 ± 0.19)
n.s.
The compounds were tested for their ability to inhibit uptake of 30 nM [3H]GABA for 3 min. All experiments were performed in triplicates in 
three–five independent experiments. The curve fittings are based on the preferred model according to the extra-sum-of-squares F test with the 
associated P, F, DFn, DFd, Frac values, and  nH1,  nH2 indicated accordingly. Non-significant (n.s.)
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SBV2-114 in the ortho and allosteric site, we conclude that 
it is sterically possible for SBV2-114 to bind to both sites 
simultaneously (Fig. 3a). In more detail, two potential bind-
ing modes for SBV2-11 in the orthosteric site as well as one 
possible binding mode in the allosteric site was identified 
(Fig. 3a). The first binding mode in the orthosteric site is 
characterized by the carboxyl group of SBV2-114, which is 
a key feature of GAT inhibitors, coordinating the sodium ion 
(Na 1) (Fig. 3b). The positively charged nitrogen of SBV2-
114, which is the second key feature of GAT inhibitors, 
forms a hydrogen bond with the backbone of Phe293. This 
residue is part of the extracellular lid which is essential for 
the translocation process and therefore also highly conserved 
among the neurotransmitter transporters [13, 48]. Finally, 
the lipophilic di-aromatic side chain of SBV2-114 expands 
into the primarily lipophilic extracellular vestibule. Since 
all interactions observed were either formed by functionally 
essential residues or ions, this binding mode was not acces-
sible to validation by mutational experiments.
Interestingly, among the top scored poses we also 
observed a second binding mode in the orthosteric site 
where the carboxyl group of SBV2-114 forms a hydrogen 
bond with the side chain of glutamine 299 (Q299) and the 
protonated nitrogen undergoes hydrogen bonding with 
Ser395 (Fig. 3c). A similar alternative binding mode was 
already discussed by Vogensen et al. [30]. The lipophilic 
aromatic side chain extends analogously to the first bind-
ing mode into the extracellular vestibule. While Ser395 
constitutes a highly conserved residue amongst the GATs 
and the monoamine transporter, Q299 is a unique residue 
for BGT1, corresponding to leucine in all other GATs (see 
alignment [46]). An interaction with this residue could pos-
sibly explain subtype selectivity and be important for the 
observed biphasic inhibition profile. This prompted us to 
investigate the activity of SBV2-114 in the hBGT1 mutant 
where we would predict a loss of activity. However, the  [3H]
GABA uptake results for the hBGT1 Q299L mutant showed 
a clear biphasic inhibition profile and no significant altered 
Fig. 3  Overview of SBV2-114 docking poses in the orthosteric site 
(yellow and orange ligands) and allosteric site (pink ligand) in a 
hBGT1 homology model (a) [37]. b Docking pose of SBV2-114 
according to the first binding mode in the orthosteric site. The car-
boxyl group coordinates a sodium ion whereas the protonated nitro-
gen forms a hydrogen bond with the backbone carbonyl of Phe253. 
The diaromatic sidechain of SBV2-114 expands into the extracellular 
vestibule. c Docking pose of the second binding mode of SBV2-114 
in the orthosteric site. The carboxyl group forms a hydrogen bond 
with the side chain of Q299L whereas the protonated nitrogen forms 
a hydrogen bond with the side chain of Ser395. The diaromatic side-
chain of SBV2-114 expands into the extracellular vestibule. d SBV2-
114 docking pose in the allosteric pocket. The carboxyl group of 
SBV2-114 undergoes hydrogen bonding with side chains of Tyr453, 
Arg61 and Gln290. The protonated nitrogen forms a hydrogen bond 
with Asp452
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activity for SBV2-114, which would contradict the second 
binding mode and the relevance of Q299 for binding (data 
not shown). Additionally, we also investigated the activity 
of SBV2-114 in the corresponding hGAT3 mutant L314Q 
mimicking the orthosteric Q299 site of hBGT1. Through 
this mutation we were able to strengthen the biphasic inhibi-
tion profile of SBV2-114 and introduce activity in hGAT3 
L314Q similar to hBGT1 underlining the potential relevance 
of Q299 for hBGT1 activity. In detail, the profile of SBV2-
114 at GAT3 L314Q had a higher F value compared to at 
hGAT3 (15.29 vs 8.14, respectively), and hence, statistically 
a more pronounced biphasic CRC, and a higher Frac value 
compared to both hGAT3 and hBGT1 (Fig. 4).
In terms of the allosteric site (third binding mode), the 
best poses showed that the carboxylic group undergoes 
hydrogen bonding with the side chains of tyrosine 453 
(Tyr453), arginine 61 (Arg61) and glutamine 290 (Gln290), 
whereas the protonated nitrogen forms a hydrogen bond with 
aspartate 452 (Asp452) (Fig. 3d). Only Tyr453 has been 
proposed by others to be relevant for subtype selectivity 
[37, 47]. Because this residue is also the only interacting 
residue not highly conserved among the GATs and mono-
amine transporters, we investigated the inhibition profile of 
SBV2-114 at the hBGT1 Y453A mutant. However, the  [3H]
GABA uptake results for the hBGT Y453A mutant did not 
show the expected decrease in activity for SBV2-114 (data 
not shown).
SBV2‑114 at High Concentrations Leads 
to an Intracellular  Ca2+ Increase
A link between changes in intracellular  Ca2+ levels and 
altered GAT1- and GAT3-mediated  [3H]GABA uptake 
has been reported [45], which prompted us to investigate if 
SBV2-114 triggers an intracellular  Ca2+ increase in tsA201 
cells transiently expressing hBGT1. As depicted in Fig. 5a, 
SBV2-114 triggered an intracellular  Ca2+ increase at 200 μM 
and 500 μM within the 3 min timeframe used for  [3H]GABA 
uptake at hBGT1. As a positive control, ATP also induced a 
 Ca2+ increase. Both effects could be blocked by pre-incuba-
tion with the membrane permeable  Ca2+ chelator BAPTA/
AM (Fig. 5a). A similar  Ca2+ response was observed in 
Fig. 4  Inhibitory activity of SBV2-114 at hBGT1, hGAT3 and 
hGAT3 L314Q transiently expressed in tsA201 cells. SBV2-114 was 
tested for its ability to inhibit uptake of 30 nM  [3H]GABA for 3 min. 
The experiments were performed in triplicate in two–three independ-
ent experiments and depicted as normalized means ± S.E.M (hBGT1 
WT) or a representative curve with mean ± S.D. The data fitting is 
based on the preferred model according to the extra-sum-of-squares 
F test, with the biphasic fit as the preferred fit for all curves P < 0.05. 
See main text for  IC50 values. Typical counts ranged from 50 to 4200 
CPM
Fig. 5  Ca2+ response of SBV2-114 in tsA201 cells transiently 
expressing hBGT1 (a) or hGAT1 (b). SBV2-114 was tested for its 
ability to induce an intracellular  Ca2+ increase determined using the 
Fluo-4  Ca2+-assay with and without the presence of 25 μM BAPTA/
AM. The experiments were performed in triplicate in three–four 
independent experiments and depicted as mean ± S.E.M. One-Way 
ANOVA followed by Dunnett’s multiple comparison test comparing 
to control levels, **P < 0.01, ***P < 0.001
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tsA201 cells expressing hGAT1 (Fig. 5b), revealing that 
the effect was not BGT1 specific, although it is unknown 
if SBV2-114 triggers a  Ca2+ response in tsA201 cells from 
internal stores or influx and through which target(s).
Next, we wanted to investigate if the biphasic CRC 
of SBV2-114 was dependent on the  Ca2+ response, and 
where the  Ca2+ originates from. To this end, tsA201 cells 
expressing hBGT1 were pre-incubated with either the cell 
impermeant  Ca2+ chelator BAPTA to abolish any possible 
 Ca2+ influx or the cell permeant BAPTA/AM to chelate 
all intracellular  Ca2+ increases in response to SBV2-114. 
It is clear from these experiments that the pre-incubation 
itself (30 min at 37 °C), both in the assay buffer (control) 
and assay buffer supplemented with BAPTA/AM, affected 
the inhibition curve of SBV2-114 at hBGT1 in the  [3H]
GABA uptake assay (Fig.  6), however without chang-
ing the  IC50 values. Specifically, lowered Frac values and 
Hill coefficients compared to Table 1 were observed both 
in the control  (IC50 = 6.1 μM and 507.0; μM,  nH1 = -0.76, 
 nH2 = -2.05; Frac = 0.21, F value = 62.75) and the BAPTA/
AM experiment  (IC50 = 5.2 μM and 512.9 μM;  nH1 = -2.02, 
 nH2 = -− 1.91; Frac = 0.15, F value = 5.61). The same sce-
nario was observed in the BAPTA experiment (data not 
shown). Consequently, it is impossible to conclude on the 
effect of chelating  Ca2+ in response to SBV2-114 alone. 
Nevertheless, although the pre-incubation affected the Frac 
values and Hill coefficients, the preferred fit was still bipha-
sic in both cases (F test), altogether indicating that the  Ca2+ 
response elicited by SBV2-114 is not responsible for the 
biphasic inhibition profile.
To address the involvement of  Ca2+ in the biphasic profile 
in another way, we tested if we could abolish the bipha-
sic profile of SBV2-114 by inhibiting any potential release 
of  Ca2+ from the endoplasmic reticulum (ER), elicited by 
SBV2-114, by inhibiting phospholipase C (PLC), or by 
blocking any SBV2-114 mediated  Ca2+ influx through the 
P2X7 receptor [49]. For this, tsA201 cells were pre-incu-
bated with either U-73122 or A 804595 for 30 min prior to 
and during the  [3H]GABA uptake. Inhibition of PLC with 
5 μM U-73122 or P2X7 with 1 μM A 804595, however, did 
not convert the biphasic profile into a monophasic curve. 
Also, we still observed that the pre-incubation had an impact 
similar to pre-incubation with BAPTA/AM on the SBV2-
114 inhibition curve at hBGT1 compared to Table 1 in terms 
of a lowered Frac value and Hill coefficients (Supplemental 
Fig. 1). Thus, it is not possible based on this approach either 
to deduce if the  Ca2+ increase is involved in the biphasic 
CRC of SBV2-114 at BGT1.
In order to avoid this pre-incubation, we tested if we 
could induce a biphasic inhibition profile of BPDBA and 
GABA by triggering  Ca2+ increases with ATP. Even though 
ATP modulated the BGT1 mediated  [3H]GABA uptake and 
decreased the total  [3H]GABA uptake by 9% (P < 0.001, 
One-way ANOVA, data not shown), the presence of ATP 
during the  [3H]GABA uptake had no effect on the type of 
inhibition profile of BPDBA and GABA at hBGT1 (Sup-
plemental Fig. 2).
Anti‑seizure Profile of SBV2‑114
Several animal studies with the GAT1/BGT1 inhibitor 
EF1502 and the BGT1 inhibitor RPC-425 have reported 
anti-seizure effects of the compounds that cannot be ascribed 
solely to GAT1 [20–23]. This, together with the better selec-
tivity of SBV2-114 (Supplemental Table 2) [46], impelled us 
to test the ability of SBV2-114 to prevent seizures in three 
mouse models. SBV2-114 was first tested in AGS Frings 
mice, which is a model of generalized seizures, to deter-
mine the ability of SBV2-114 to prevent sound-induced sei-
zures and determine the approximate TPE for further test-
ing. Frings mice were injected with 50 mg/kg SBV2-114 
i.p. and tested after 15, 30, and 60 min. A subsequent time 
response study was conducted at a dose of 120 mg/kg and 
testing after 30, 60, and 120 min. The results from these 
studies show that SBV2-114 is brain-permeant and blocks 
sound-induced seizures in Frings mice in a dose-dependent 
manner at a TPE of 15 min (Table 3). Yet, a faster TPE can-
not be excluded. In the subsequent MES test, SBV2-114 was 
administered at doses ranging from 50 to 200 mg/kg 15 min 
prior to the MES stimulus. SBV2-114 also prevented the 
seizures in the MES test and with an  ED50 of 139 mg/kg. 
Fig. 6  Inhibitory activity of SBV2-114 at hBGT1 transiently 
expressed in tsA201 cells and the effect of BAPTA/AM. Cells were 
pre-incubated 30 min with assay buffer ± 25 µM BAPTA/AM before 
SBV2-114 was tested for its ability to inhibit uptake of 30 nM  [3H]
GABA for 3  min. The experiment shown is a representative exam-
ple performed in triplicate and depicted as means ± S.D. According to 
the extra-sum-of-squares F test, the biphasic fit was preferred for both 
conditions P < 0.05
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However, SBV2-114 produced rotarod impairment with a 
 TD50 of 163 mg/kg, and with 95% confidence intervals over-
lapping with the  ED50. In the s.c.PTZ seizure test we only 
examined a single higher dose of 150 mg/kg SBV2-114. At 
this dose, SBV2-114 did not block s.c.PTZ-induced seizures 
or produce rotarod impairment (Table 3). The reason for the 
mixed effect of SBV2-114 at rotarod impairment between 
the CF1 mice tested in the MES test and the s.c.PTZ seizure 
test is unclear. Further studies are needed to address if this 
could be due to e.g. sedative effects of SBV2-114.
Selectivity Studies of SBV2‑114
Despite its dual activity at GAT1 and BGT1, EF1502 is 
completely devoid of any activity at a broad range of neuro-
transmitter systems including adrenergic, GABAergic and 
dopaminergic receptors in a radioligand binding study of 
74 different neuroreceptors and ion channels [21]. Since 
SBV2-114 belongs to the same compound class as EF1502, 
and displayed anti-seizure effects, we wanted to address 
the overall selectivity of SBV2-114 in an effort to probe 
its potential as a tool compound to study BGT1 function 
in vivo. Hence, the selectivity of SBV2-114 for BGT1 over 
42 neuroreceptors and transporters was tested in a similar 
manner as EF1502 through an affinity screening program 
supported by NIMH PDSP. From this evaluation, it is clear 
that SBV2-114 is fairly nonselective and competes with 
the radioligand binding to a number of other known drug 
targets including the serotonin receptors (5-HT2B 5-HT2C, 
5-HT5A, and 5-HT6), the adrenergic receptor  alpha2A, and 
the dopamine transporter (DAT) (see Supplemental Table 4 
for details) consequently hampering the usability of SBV2-
114 to study BGT1 function in vivo. Additional studies are 
needed to investigate if interaction with any of these targets 
are implicated in the biphasic inhibition profile of SBV2-
114 at hBGT1 in which case they would have to be endog-
enously expressed in our cell lines. Most likely, the involve-
ment of any serotonin receptors and the adrenergic receptor 
 alpha2A can be disregarded, since they are not endogenously 
expressed in HEK-293 cells [50].
Table 3  Anti-seizure effects 
of SBV-114 in the audiogenic 
induced seizure test, the MES 
test, and the s.c.PTZ seizure 
threshold test
Toxicity was tested in all experiments by the Rotarod test where minimal motor impairment was tested 
prior to the induced seizure
a SBV-114 (50 and 120 mg/kg) was administered i.p. and seizures were induced in AGS Frings mouse by a 
sound stimulus of 11 kHz (110 decibel) for 20 s at different time points. Mice were considered protected if 
they failed to display full hind limb tonic extension seizure
b SBV-114 (50, 100, 125, 150, and 200  mg/kg) was administered i.p.in CF-1 mice and seizures were 
induced after 15 min by electrodes placed on the eyes with a 50 mA (60 Hz) alternating current for 0.2 s. 
Mice were considered protected if they failed to display full hind limb tonic extension seizure
c SBV2-114 (150 mg/kg) was administered i.p. in CF-1 mice and seizures were induced after 15 min by a 
s.c. dose of PTZ (85 mg/kg). The mice were considered protected if they failed to display clonic seizures 
characterized by minimal forelimb clonus and/or vibrissae twitching
 Dose (mg/kg) Time (min) #Protected/#Tested #Motor impairment/#Tested
Audiogenic induced  seizurea
 50 15 3/4 0/3
30 2/4 0/3
60 1/4 0/3
120 0/4 0/3
 120 30 4/4 0/4
60 3/4 0/4
120 2/4 0/4
240 1/4 0/4
Maximal electroshock seizure (MES)b
 50 15 0/3 0/3
 100 15 0/4 0/4
 125 15 2/7 0/7
 150 15 4/6 2/6
 200 15 4/4 3/4
s.c.PTZ seizure threshold  testc
 150 30 0/8 0/8
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Discussion
Based on the detailed molecular characterization of SBV2-
114 using the  [3H]GABA uptake assay, it is clear that SBV2-
114 inhibits the GATs in an atypical manner. We have dem-
onstrated an apparently novel biphasic inhibition profile 
of SBV2-114, which is most evident at BGT1. At BGT1, 
SBV2-114 has an  IC50 value in the low μM range (m/hBGT1: 
3.9/4.7 μM) inhibiting a fraction of 0.42–0.45 of the BGT1-
mediated GABA uptake, while the second  IC50 is in the high 
μM range (m/hBGT1: 402.7/555.9 μM). Additionally, we 
show that the high affinity component of the biphasic profile 
of SBV2-114 was most evident when the Frac value (% inhi-
bition) and potency was high, as is the case for BGT1 com-
pared to the other GATs. We further show that (R)-EF1502 
and other SBV2-114 analogues, all sharing the β-amino 
acid moiety attached to di-aromatic lipophilic side-chains, 
inhibit BGT1 in a biphasic manner. The reason why there 
are no prior notions of (R)-EF1502 having a biphasic profile 
is likely due to the fact that the  [3H]GABA uptake assay is 
typically performed with 8-point CRCs and not 12 and is 
thus problematic to capture. By contrast, BGT1 inhibitors 
such as BPDBA and NNC 05-2090, which comprise dif-
ferent scaffolds compared to SBV2-114, as well as GABA 
itself, display regular monophasic inhibition curves, support-
ing the finding that the biphasic profile at BGT1 is reserved 
to the class of structurally related compounds to SBV2-114 
only. Importantly, we show that this biphasic inhibition pro-
file of SBV2-114 at BGT1 in  [3H]GABA uptake is indeed a 
true phenomenon as it occurs regardless of species, origin 
of the transporters (recombinant vs endogenous), expression 
levels, and kinetics.
Recently, it was demonstrated that the highly related 
human serotonin transporter comprises an additional allos-
teric binding site in the extracellular vestibule above the 
orthosteric site [15]. This prompted us to investigate whether 
a similar allosteric site exists in BGT1 which could accom-
modate SBV2-114, and hence, could explain the observed 
biphasic behaviour. With the help of a homology model 
based on the SERT crystal structure along with docking 
studies, we identified hBGT1 Q299L in the orthosteric 
site and hBGT1 Tyr453 in the allosteric site to be possibly 
involved in SBV2-114 binding (Fig. 3). Furthermore, the 
top scored docking poses of SBV2-114 in the orthosteric 
and allosteric site suggested that it is sterically feasible for 
SBV2-114 to bind to both sites simultaneously (Fig. 3a). 
Nevertheless, we were not able to alter the biphasic inhibi-
tion profile of SBV2-114 by introducing a single mutation 
in the orthosteric site (hBGT1 Q299L) or the allosteric site 
(hBGT1 Y453A). However, by introducing a glutamine in 
hGAT3 at the position L314Q, which corresponds to Q299L 
in the orthosteric site of hBGT1, an increase in the activity 
of SBV2-114 and a strengthening of the biphasic profile was 
observed. Thus, residue Q299 in hBGT1 and residue L314 
in hGAT3 appear to be important for the binding and activ-
ity of SBV2-114, but not solely responsible for the bipha-
sic inhibition profile considering the unaltered inhibition 
profile of SBV2-114 at hBGT1 Q299L. The latter could be 
the result of possible compensation since the docking stud-
ies suggest that SBV2-114 can adopt two slightly different 
binding modes in the orthosteric pocket where the carboxyl 
group of SBV2-114 either interacts with the sodium ion Na1 
or undergoes hydrogen bonding with Q299L (Fig. 3b and 
c). Lastly, the  [3H]GABA uptake data clearly shows that 
SBV2-114 inhibits GATs in an atypical manner, and hence, 
it is possible that other interacting residues not specific to 
BGT1 are accountable for the biphasic inhibition profile of 
SBV2-114.
To address the link between  Ca2+, altered  [3H]GABA 
uptake [45], and the potential involvement in the bipha-
sic inhibition profile of SBV2-114, we first demonstrated 
that SBV2-114 triggered an intracellular  Ca2+ increase at 
high concentrations independent of BGT1, via an unknown 
mechanism. Additionally, we showed that ATP, which trig-
gered a large increase in intracellular  Ca2+ levels, lowered 
the BGT1-mediated  [3H]GABA uptake, supporting that a 
change in intracellular  Ca2+ levels modulate BGT1 activity 
as reported for GAT1 and GAT3 [45]. Nevertheless, the sub-
sequent studies aimed at reducing the  Ca2+ involvement in 
the biphasic inhibition profile of SBV2-114 at hBGT1 were 
inconclusive. Thus, further studies are needed to investi-
gate if the intracellular  Ca2+ increase triggered by the high 
concentrations of SBV2-114 is implicated in the observed 
biphasic behaviour, especially since the least potent part of 
the biphasic inhibition curve lies in the same range as the 
 Ca2+ releasing concentrations of SBV2-114.
Although a biphasic inhibition profile for the subfamily 
of GABA transporters has not been noted before, the phe-
nomenon has been described within the family of SLC6A 
transporters [51–54]. A biphasic activity of a small molecule 
ATM7 has been reported at SERT, and was explained by an 
enhanced SERT uptake in response to nM concentrations of 
ATM7, while ATM7 inhibited SERT uptake at μM concen-
trations [53], with no notion of two binding sites for ATM7 
at SERT. A mechanism like that for SBV2-114, however, is 
not in agreement with the  [3H]GABA uptake data presented 
here, since nM concentrations of SBV2-114 decreased the 
total  [3H]GABA uptake. Another example comes from a 
truncated version of the human DAT, which displayed a 
biphasic inhibition profile of  [3H]DA uptake presumably 
due to two DAT populations with different affinities for 
dopamine [51, 55]. The fact that a biphasic inhibition pro-
file of SBV2-114 was observed in cells transiently express-
ing BGT1 argues against the possibility that two BGT1 
populations underlie the biphasic profile observed. Last, 
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it seems unlikely that the presumed dimerization of BGT1 
[56, 57] accounts for the biphasic profile of SBV2-114 at 
BGT1, since other BGT1 inhibitors including NNC 05-2090, 
BPDBA as well as GABA inhibit BGT1 in a monophasic 
manner. If not, then a specific binding mode of SBV2-114 
to the dimer should be in play.
BGT1 has attracted attention as a potential target for sei-
zure management due to animal studies demonstrating anti-
seizure properties of the GAT1/BGT1 inhibitor EF1502 and 
the BGT1 inhibitor RPC-425 [20–23]. Still, the unaltered 
seizure susceptibility reported in BGT1 KO mice has ques-
tioned the importance of BGT1 as such [26], and BGT1 
selective compounds are warranted to clarify the role of 
BGT1 in epilepsy. As reported here, SBV2-114 is indeed 
more selective for mBGT1 over mGAT1-3  (IC50 > 1000 μM) 
as compared to both EF1502 and RPC-425 [46], which is an 
intriguing finding demonstrating how much a small chemi-
cal change from EF1502 to SBV2-114 can affect selectivity. 
The improved BGT1 preference of SBV2-114 encouraged us 
to test the anti-seizure properties of SBV2-114. We report 
that SBV2-114 dose-dependently prevented both audiogenic 
induced seizures in Frings mice and maximal electroshock 
induced seizures in CF-1 mice. In contrast, SBV2-114 did 
not prevent a minimal clonic seizure in the s.c.PTZ test at 
the dose (150 mg/kg, i.p) and pre-treatment time (30 min) 
tested. Though, this might be due to the apparent fast phar-
macokinetics of SBV2-114 according to the testing in Frings 
mice illustrating that SBV2-114 was most effective at the 
earliest time point tested (15 min). Despite SBV2-114’s pref-
erence for mBGT1 over mGAT1-3, results from the NIMH 
PDSP screen of neuro targets suggest that SBV2-114 also 
interacts with other molecular targets; a finding that ren-
ders it difficult to conclude that the anti-seizure effect of 
SBV2-114 is solely related to BGT1 inhibition. Nonetheless, 
the only known shared target for EF1502, RPC-425, and 
SBV2-114 is BGT. This, coupled with the fact that EF1502 
has a good overall selectivity profile [21], collectively sup-
ports a role for BGT1 in epilepsy. This is in agreement with 
the synergistic effects of EF1502 and tiagabine in epilepsy 
models that cannot be linked to GAT1 exclusively [20–23]. 
Of note, the effect of combining RPC-425 and tiagabine did 
not have synergistic but only additive effects, which might 
be explained by differences in the pharmacokinetics between 
EF1502 and RPC-425 [20] rather than dismissing the impor-
tance of BGT1 in epilepsy.
Future Directions
While the molecular mechanism underlying the biphasic 
inhibition profile of SBV2-114 at BGT1 remains elusive, 
we show that it is a consistent phenomenon for this class 
of compounds all sharing a β-amino acid moiety attached 
to di-aromatic lipophilic side-chains. Although the in vivo 
suitability of SBV2-114 is poor due to its low selectivity and 
narrow therapeutic index, the data support previous find-
ings suggesting an anti-seizure role for BGT1 inhibition. 
Further, SBV2-114 still constitutes a valuable in vitro tool 
compound to identify molecular mechanisms modulating 
GABA uptake, specifically the biphasic inhibition profile, 
and as a lead compound for the design of more selective 
BGT1 inhibitors. Ideally such studies would be aided by a 
BGT1 inhibitor radioligand for binding studies.
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